Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Acute myeloid leukemia (AML) remains a difficult disease to treat disease. In a phase 2 clinical trial in patients with relapsed/refractory AML, combining the hypomethylating agent, azacitidine, with the PD-1 checkpoint inhibitor, nivolumab, demonstrated encouraging response rates (33%), median even...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Hussein A., Alaniz, Zoe, Mackay, Sean, Cyr, Matthew, Zhou, Jing, Issa, Ghayas C., Alfayez, Mansour, Matthews, Jairo, Kornblau, Steven M., Jabbour, Elias, Garcia-Manero, Guillermo, Konopleva, Marina, Andreeff, Michael, Daver, Naval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759127/
https://www.ncbi.nlm.nih.gov/pubmed/34555853
http://dx.doi.org/10.1182/bloodadvances.2021004583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759127/
https://www.ncbi.nlm.nih.gov/pubmed/34555853
http://dx.doi.org/10.1182/bloodadvances.2021004583

Ejemplares similares